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Abstract
Xanthine oxidase (XO) generates reactive oxygen metabolites (ROM) as a by-product while catalyzing their reaction. The
present study implicates these ROM in the pathogenesis of liver necrosis produced in rats by the intraperitoneal
administration of thioacetamide (TAA; 400 mg/kg b.wt.). After 16 h of TAA administration, the activity of rat liver XO
increased significantly compared to that of the control group. At the same time, the level of serum marker enzymes of liver
necrosis (aminotransferases and alkaline phosphatase) and tissue malondialdehyde content also increased in TAA treated
rats. Tissue malondialdehyde concentration is an indicator of lipid peroxidation and acts as a useful marker of oxidative
damage. Pretreatment of rats with XO inhibitor (4-hydroxypyrazolo[3,4-d]pyrimidine; allopurinol (AP)) followed by TAA
could lower the hepatotoxin-mediated rise in malondialdehyde level as well as the level of marker enzymes associated with
liver necrosis. The survival rate also increased in rats given AP followed by the lethal dose of TAA. In either case, the effect of
AP was dose-dependent. Results presented in the paper indicate that increased production of XO-derived ROM contributes
to liver necrosis, which can be protected by AP. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Necrosis of liver is a complex process involving
swelling of the cells and loss of plasma membrane
integrity leading to cell lysis, and consequently to
hepatic failure. Virus, drugs and chemicals are
among the factors, which may lead to necrosis and
subsequent liver failure [1]. Thioacetamide (TAA), a
thiono-sulfur-containing compound endowed with
liver damaging activity, is often used to induce ex-
perimental liver necrosis in animal species [2^4].
Shortly after administration, TAA undergoes an ex-
tensive metabolism to acetamide and thioacetamide
S-oxide by the mixed function oxidase system [5].
The monooxygenase system further metabolizes thio-
acetamide S-oxide to thioacetamide S-dioxide, which
is capable of binding to tissue macromolecules and is
thought to produce damage [6,7]. Also, partially re-
duced cytotoxic oxygen moieties (reactive oxygen
metabolites, ROM) have been implicated in the ne-
crotic process induced by TAA [2,3]. The occurrence
of extensive radical reactions in the liver during the
necrotic process has been reported in the Wistar
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strain of rat [3]. Based on the decrease of the liver
concentrations of vitamins C and E and the forma-
tion of lipid hydroperoxides after TAA administra-
tion, an increase in oxidative stress by TAA has been
suggested by Sun et al. [3]. The cellular source lead-
ing to excess generation of ROM after TAA expo-
sure has, however, not been established.
ROM have been held responsible for the patho-
genesis of many forms of tissue injuries. When the
cells are exposed to excess ROM, oxidative damage
occurs which a¡ects many cellular functions that
trigger cell death. In the present investigation, evi-
dence is provided for the involvement of ROM in
the necrosis produced by TAA. Xanthine oxidase
(XO), the enzyme which generates ROM as a by-
product while catalyzing their reaction, is reported
here to increase in TAA treated rats and is suggested
to initiate the necrotic process. Evidence is provided
to establish the role of XO-derived ROM in the ne-
crotic process, taking the hepatic malondialdehyde
content as an index to evaluate oxidative damage.
A variety of antioxidants scavenge free radicals and
prevent oxidative damage in the cell. The primary
defense against oxidative damage in the tissue rests
with antioxidants such as the tripeptide glutathione
(GSH), which is consumed in order to counteract the
e¡ects of oxidative stress [3]. The concentration of
reduced GSH in rat liver was, therefore, determined
as another type of index of oxidative stress produced
by TAA. In vivo XO inhibitor, 4-hydroxypyrazo-
lo[3,4-d]pyrimidine (allopurinol, AP), is shown to
protect the tissue against TAA-induced liver necrosis
in a dose-dependent manner.
2. Materials and methods
2.1. Animals and other material
Adult female albino Wistar rats (weighing 150^200
g) were obtained from and kept in the Central Ani-
mal House Facility of Jamia Hamdard in propylene
cages in an environmentally controlled room with a
12 h light^dark cycle at constant room temperature
(24 þ 2‡C). Animals had free access to a standard
pellet diet and tap water ad libitum. Guidelines is-
sued by the Jamia Hamdard Animal Ethics Commit-
tee for the care and use of laboratory animals were
followed. For experimental purpose, animals were
randomly assigned to di¡erent groups, with six ani-
mals in each cage. Chemicals used in this study were
of the highest purity grade available from standard
commercial sources in India. Diagnostic kits were
purchased from Span Diagnostics (India). TAA
was procured from Sigma (St. Louis, MO, USA).
2.2. Induction of liver necrosis and its evaluation by
analytical methods
Liver necrosis was induced in rats by a single in-
traperitoneal injection of TAA (400 mg/kg b.wt.),
dissolved in saline (0.9% NaCl), as previously de-
scribed [4]. Control rats received a similar volume
of normal saline by the same route. Liver injury
was evaluated by analyzing serum/tissue lysate ob-
tained from the animals sacri¢ced 16 h after the
TAA administration. Rats were anesthetized with
ether and the blood was drawn by cardiac puncture.
Blood was allowed to clot and the serum was sepa-
rated by centrifugation. Serum was used for the anal-
yses of aminotransferases and alkaline phosphatase
levels using diagnostic kits, based on the methods of
Reitman [8] and Bessey [9], respectively. Other bio-
chemical estimations were performed on a 10% tissue
homogenate (lysate) prepared from the liver. The
liver of the animal was immediately removed, washed
in ice-cold saline solution, blotted and a small por-
tion was cut and weighed for homogenization. All
the subsequent operations were carried out at 0^4‡C.
Tissue lysate was prepared in nine volumes of
0.1 M phosphate bu¡er (pH 7.4) containing 1.15%
KCl, using a polytron homogenizer. A portion of the
lysate was kept for the determination of hepatic ma-
londialdehyde content [10] and the content of re-
duced GSH [11]. The rest of the lysate was subjected
to di¡erential centrifugation in a cooling centrifuge
initially at 800Ug for 10 min to remove the nuclei
and other cell debris, and then the resultant super-
natant was centrifuged at 9500Ug for 20 min to get
the post-mitochondrial supernatant (PMS). The PMS
was used to measure the speci¢c activity of XO [12].
The protein content of each sample was determined
according to Lowry’s method [13] using bovine se-
rum albumin as reference protein. All the biochemi-
cal estimations were completed on the day the ani-
mals were sacri¢ced.
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2.3. Experimental design for evaluating the
anti-hepatotoxic activity of AP
Anti-hepatotoxic activity of XO inhibitor AP was
demonstrated at di¡erent dose levels of the drug.
Various doses of AP, viz. 7.5, 15 or 30 mg/kg
b.wt., prepared in distilled water, were administered
to rats orally for three consecutive days (at 24 h
intervals) followed by the administration of TAA
(400 mg/kg b.wt., i.p.). TAA was given an hour after
the last dose of AP was administered. The groups of
rats receiving various doses of AP followed by TAA
are referred to as AP7:5, AP15, and AP30. The groups
treated with TAA alone and with the highest dose of
AP (30 mg/kg b.wt.) alone served as the positive
control groups. All the biochemical parameters men-
tioned in Section 2.2 of this text were estimated in
the experimental and the control group of rats sacri-
¢ced 16 h after TAA administration.
2.4. Survival studies
These experiments were performed to examine the
protective e¡ect of AP on survival in rats receiving a
lethal dose of TAA (i.e. 150 mg/kg b.wt., p.o., daily,
for 12 consecutive days). Animals for these studies
were divided into ¢ve groups, each containing 10
rats. Three groups were given orally di¡erent doses
of AP (7.5, 15 or 30 mg/kg b.wt., for three consec-
utive days) followed after 1 h by the administration
of the lethal dose of TAA. The fourth and the ¢fth
groups were given, respectively, the lethal dose of
TAA alone and the highest dose of AP alone. Mor-
tality in each group was recorded daily for a week
after the last dose of TAA was administered. Nine
out of 10 rats died in the fourth group (the group
given the lethal dose of TAA), while no mortality
was observed in the ¢fth group (i.e. the group receiv-
ing 30 mg AP/kg b.wt.). Results are expressed as the
number of rats that survived in each group.
The protective e¡ect of XO inhibition on survival
was further investigated using tungsten. Tungsten
has a molybdenum-antagonistic e¡ect and, when
gavaged to rats as sodium tungstate (ST), it inhibits
the activity of XO, which is a molybdoprotein. Ani-
mals were gavaged with ST (50 mg/kg b.wt., daily,
for 7 weeks) followed by the above mentioned lethal
dose of TAA. Survival was calculated 2 weeks after
the last dose of TAA was administered. The group of
rats receiving the lethal dose of TAA alone served as
the control group. No mortality was observed in the
group of rats given the same dose of ST for a similar
duration of time.
2.5. Statistical analysis
Data are expressed as means þ S.E.M. and ana-
lyzed by one-way analysis of variance combined
with Newman^Keuls test. The level of statistical sig-
ni¢cance was chosen as P6 0.05.
3. Results
3.1. E¡ect of TAA on biochemical parameters
associated with liver necrosis
Serum levels of alanine aminotransferase (sALT),
aspartate aminotransferase (sASP) and alkaline
phosphatase (sALP) were measured and found to
be elevated signi¢cantly (Table 1) in rats sacri¢ced
16 h after receiving a necrogenic dose of TAA (400
mg/kg b.wt., i.p.). These results indicate liver injury
after TAA exposure, as described previously [2,4].
Table 1
Serum levels of enzymes associated with TAA-induced liver necrosis in rats
Treatment Biochemical markers of liver necrosis
sALT (IU/ml) sASP (IU/ml) sALP (Eq. U/ml)
Control 35.9 þ 0.83 127.7 þ 2.07 7.1 þ 0.03
Thioacetamide 113.6 þ 0.86* 182.9 þ 2.83* 9.4 þ 0.05*
Enzyme activity was determined 16 h after a single intraperitoneal injection of TAA (400 mg/kg b.wt.) as per Section 2. Control rats
received saline in place of TAA. Values are means þ S.E.M. of six rats and asterisks indicate signi¢cant di¡erence from the corre-
sponding control group, *P6 0.05. sALT: serum alanine aminotransferase; sASP: serum aspartate aminotransferase; sALP: serum al-
kaline phosphatase.
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Hepatic malondialdehyde content also increased sig-
ni¢cantly after TAA administration to rats (Table 2)
suggesting that the damage is oxidative. Oxidative
damage is the result of oxidative stress produced
due to the increased generation of ROM, which sub-
sequently interfere with cellular macromolecules
(such as the membrane lipids) leading to tissue in-
jury. Formation of the aldehydic products like ma-
londialdehyde is generally considered as a reliable
indicator of oxidative stress. An increase in the ma-
londialdehyde content of the tissue indicates the in-
volvement of ROM in the necrotic process. Excess
generation of ROM in TAA treated rats can be at-
tributed to the increased activity of XO (Table 2),
which generates ROM while catalyzing its reaction.
An increase in tissue reduced GSH level is also
observed in TAA treated rats (Table 2). As already
mentioned, enhanced radical reactions are expected
to consume the endogenous tissue antioxidants such
as reduced GSH, thereby depleting its concentration
within the tissue. Tissue GSH level can, therefore, act
as another type of index of oxidative damage [3].
Depletion in the hepatic GSH concentration suggests
the involvement of oxidative stress in the pathogen-
esis of liver necrosis produced by TAA. Correlating
to the changes in the malondialdehyde level of the
tissue (which increased after TAA treatment), a de-
crease in the hepatic GSH concentration was ob-
served in TAA treated rats (Table 2). This seems to
be the result of an e¡ort by the tissue to counteract
Table 2
Hepatic XO activity, malondialdehyde content and reduced GSH level in rats receiving a single injection of TAA
Biochemical parameters Control Thioacetamide
Xanthine oxidase (Wmol uric acid/mg protein) 320 þ 4.63 520 þ 8.57*
Lipid peroxidation (nmol malondialdehyde/g liver) 15.4 þ 1.3 22.3 þ 0.07*
Reduced GSH content (Wmol/g liver) 311 þ 13.6 149 þ 15.8*
Biochemical analyses were performed on the tissue samples obtained from rats sacri¢ced 16 h after the administration of a single nec-
rogenic dose of TAA according to Section 2. Control rats received normal saline instead of TAA. Values are means þ S.E.M. of six
rats and asterisks indicate signi¢cant di¡erence from the corresponding control group, *P6 0.05.
Fig. 1. sALT level in the rats treated with AP followed by a
single necrogenic dose of TAA. The value of AP alone shown
in the ¢gure is the value obtained from the group of rats re-
ceiving a dose of 30 mg/kg b.wt. for three consecutive days.
AP7:5, AP15 and AP30 indicate di¡erent doses of AP (viz. 7.5,
15, 30 mg/kg b.wt.) given for three consecutive days prior to
the administration of TAA (400 mg/kg b.wt.). Animals were
sacri¢ced 16 h following TAA administration. *P6 0.05 (n = 6),
when the AP pretreated groups were compared with the TAA
alone treated group. The decrease in TAA associated rise in the
enzyme activity is dependent upon the dose of AP. AP: allo-
purinol; TAA: thioacetamide; NC: normal control.
Fig. 2. sASP activity level in rats treated with AP followed by
a necrogenic dose of TAA (400 mg/kg b.wt.). The value of AP
alone (AP30) shown in the ¢gure is the value obtained from the
group of rats given a dose of 30 mg/kg b.wt. for three consecu-
tive days. AP7:5, AP15 and AP30 indicate di¡erent doses of AP
(viz. 7.5, 15, 30 mg/kg b.wt.) given for three consecutive days
prior to the administration of TAA. Animals were sacri¢ced 16
h following TAA administration. *P6 0.05 (n = 6), when the
AP pretreated groups were compared with the TAA alone
treated group. The decrease in TAA associated rise in the en-
zyme activity is dependent upon the dose of AP. AP: allopuri-
nol; TAA: thioacetamide; NC: normal control.
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the cytotoxic e¡ect of XO-derived ROM, generated
in excess after TAA exposure.
3.2. Alleviation by AP of TAA-induced rise of serum
markers of hepatic lesions (necrosis)
Activity levels of sALT, sASP and sALP were
measured in rats given various doses of AP followed
by TAA. Dose-dependent reductions in the activity
levels of these biochemical parameters associated
with necrotic lesions are shown in Figs. 1^3. AP
pretreatment could signi¢cantly control the TAA-in-
duced rise in the activity level of serum transami-
nases (aminotransferases) and sALP. The values
were almost brought down to normal in the rats
receiving 30 mg/kg b.wt. of AP (AP30). Pretreatment
of rats with AP is, therefore, observed to protect liver
necrosis.
3.3. Hepatic malondialdehyde level and reduced GSH
concentration in rats given AP followed by TAA
TAA administration promoted lipid peroxidation
(as indicated by a rise in tissue malondialdehyde lev-
el, Table 2), and lowered the level of GSH in rat liver
(Table 2). Contrary to the e¡ect of TAA treatment
alone, pretreatment with AP followed by TAA could
alleviate the TAA-induced rise in lipid peroxidation
(Fig. 4) in a dose-dependent manner. This alleviation
can be attributed to the ability of AP to inhibit XO,
thereby inhibiting the generation of XO-derived
ROM, which are proposed to lead to liver necrosis.
An increase in reduced GSH content of the hepatic
tissue was also observed in the group of rats pre-
treated with AP. The e¡ect of various doses of AP
on GSH level is shown in Fig. 5. While the admin-
istration of TAA led to a marked decrease in GSH
concentration, the pretreatment of rats with AP fol-
lowed by TAA could cause a rise in hepatic GSH
level. As shown in Fig. 5, the e¡ect is dependent
on the dose of AP.
3.4. Activity of hepatic XO in rats receiving AP
before the administration of TAA
Fig. 6 illustrates the results of the e¡ects of various
doses of AP on TAA-induced rise in the activity of
Fig. 3. Activity of sALP in rats treated with AP followed by a
necrogenic dose of TAA. The value of AP alone (AP30) shown
in the ¢gure is the value obtained from the group given a dose
of 30 mg/kg b.wt. for three consecutive days. AP7:5, AP15 and
AP30 indicate di¡erent doses of AP (viz. 7.5, 15, 30 mg/kg
b.wt.) given for three consecutive days prior to the administra-
tion of TAA (400 mg/kg b.wt.). Animals were sacri¢ced 16 h
following TAA administration. *P6 0.05 (n = 6), when the AP
pretreated groups were compared with the TAA alone treated
group. The decrease in TAA associated rise in the enzyme ac-
tivity is dependent upon the dose of AP. AP: allopurinol;
TAA: thioacetamide; NC: normal control.
Fig. 4. Hepatic lipid peroxidation, measured as malondialde-
hyde content, in rats treated with AP followed by a single nec-
rogenic dose of TAA. The value of AP alone (AP30) shown in
the ¢gure is the value obtained from the group given a dose of
30 mg/kg b.wt. for three consecutive days. An increase in lipid
peroxidation is observed in rats receiving TAA alone. Treat-
ment with AP prior to TAA administration could signi¢cantly
alleviate the levels of tissue malondialdehyde. AP7:5, AP15 and
AP30 indicate di¡erent doses of AP (viz. 7.5, 15, 30 mg/kg
b.wt.) given for three consecutive days prior to the administra-
tion of TAA (400 mg/kg b.wt.). Animals were sacri¢ced 16 h
following TAA administration. *P6 0.05 (n = 6), when the AP
pretreated groups were compared with the TAA alone treated
group. AP: allopurinol; TAA: thioacetamide; NC: normal
control; MDA: malondialdehyde.
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XO in rat liver. Treatment with AP followed by
TAA could inhibit the TAA-induced rise in XO ac-
tivity. The e¡ect is very much dependent on the dose
of AP, and at a dose of 30 mg/kg b.wt., the enzyme
activity was observed to be within the control limit.
Further, decreased XO activity is clearly seen to be
associated with a reduction in tissue malondialde-
hyde content (Fig. 6 versus Fig. 4), suggesting that
the treatment with the inhibitor could alleviate the
damage process, which involved ROM. The results
shown in Figs. 1^4 correlate the inhibition of XO
activity (consequently, of the generation of XO-de-
rived ROM) with the suppression of necrosis as man-
ifested by the reduction in the levels of biochemical
parameters raised after TAA treatment.
3.5. E¡ect of XO inhibitors on the TAA-induced
lethality in rats
The lethal dose of TAA killed nine out of 10 rats.
Pretreatment of di¡erent groups of rats with various
doses of AP (AP7:5, AP15, or AP30) for three consec-
Fig. 5. Reduced GSH concentration in the liver tissue of rats
pretreated with AP followed by a single necrogenic dose of
TAA. Animals were sacri¢ced 16 h following TAA administra-
tion. The value of AP alone (AP30) shown in the ¢gure is the
value obtained from the group of rats receiving a dose of 30
mg/kg b.wt. for three consecutive days. Treatment with AP pri-
or to TAA could markedly enhance the amount of reduced
GSH in the tissue. AP7:5, AP15 and AP30 indicate di¡erent
doses of AP (viz. 7.5, 15, 30 mg/kg b.wt.) given for three con-
secutive days prior to the administration of TAA (400 mg/kg
b.wt.). *P6 0.05 (n = 6), when the AP pretreated groups were
compared with the TAA alone treated group. AP: allopurinol;
TAA: thioacetamide; NC: normal control; GSH: reduced
GSH.
Fig. 6. E¡ect of AP pretreatment on TAA-induced rise in the
activity of hepatic XO in rats. The value of AP alone (AP30)
shown in the ¢gure is the value obtained from the group given
a dose of 30 mg/kg b.wt. for three consecutive days. AP7:5,
AP15 and AP30 indicate di¡erent doses of AP (viz. 7.5, 15, 30
mg/kg b.wt.) given for three consecutive days prior to the ad-
ministration of a single necrogenic dose of TAA (400 mg/kg
b.wt.). The animals were sacri¢ced 16 h after TAA administra-
tion. *P6 0.05 (n = 6), when the AP pretreated groups were
compared with the TAA alone treated group. AP: allopurinol;
TAA: thioacetamide.
Fig. 7. Survival rate in rats receiving AP followed by the lethal
dose of TAA. Rats were given AP for three consecutive days
before administering the lethal dose of TAA. Dose and mode
of administration of the hepatotoxin have been described in
Section 2. The value of the AP alone treated group (AP30) is
the value obtained from the group given 30 mg AP/kg b.wt. for
three consecutive days. AP7:5, AP15 and AP30 indicate di¡erent
doses of AP (viz. 7.5, 15, 30 mg/kg b.wt.) given for three con-
secutive days before the administration of the lethal dose of
TAA. Survival was observed daily. Nine out of 10 rats died in
the group receiving the lethal dose of TAA. AP pretreatment
could increase the survival rate in rats receiving the lethal dose
of TAA. AP: allopurinol; TAA: thioacetamide.
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utive days prior to the administration of the lethal
dose of TAA resulted in an appreciable decrease in
mortality. The e¡ect on survival, as shown in Fig. 7,
is dependent on the dose of AP. The group of rats
pretreated with a dose of AP30 exhibited a decrease
in mortality up to 60% in comparison to the rats
receiving the lethal dose of TAA alone. No mortality
was observed in the group receiving AP alone. Tung-
sten, which is another inhibitor of XO, was also
found to protect the rats against TAA-induced le-
thality (Fig. 8).
4. Discussion
A number of drugs, chemicals and also virus have
been reported to cause liver necrosis, which some-
times becomes di⁄cult to manage by medical thera-
pies [14,15]. E¡ective protective agents may provide a
choice for the patients at risk of hepatic failure due
to severe necrosis. In the present study, we examined
the potential of XO-derived ROM in producing ne-
crosis. In vivo XO inhibitor AP is shown to be an
e¡ective anti-hepatotoxic agent when given prophy-
lactically to rats.
Several studies have employed TAA to produce a
model of hepatic necrosis in experimental animals
[3,4,16]. The necrotic model induced by TAA in
rats proved to be a reliable and satisfactory model
[2]. The necrogenic dose of TAA administered to rats
could cause a signi¢cant increase in sALT, sAST and
sALP levels in rats sacri¢ced 16 h following TAA
administration (Table 1). These results indicate liver
necrosis and are consistent with the literature [2^4].
The production of hepatic injury by TAA is
thought to be the result of binding of some of the
TAA metabolites to cellular macromolecules [5^7].
In addition, radical reactions are suggested to be in-
volved in the pathogenesis of liver injury caused by
TAA [2]. To elucidate the possible role of ROM in
the mechanism underlying TAA hepatotoxicity, the
activity of rat liver XO was determined. Our data
reveal that XO activity in rat liver is increased and,
due to its ability to generate ROM, oxidative stress is
produced, which is suggested to contribute to liver
necrosis.
Structural and functional alterations associated
with the exposure of the tissue to a wide variety of
factors including many chemicals are understood to
be mediated by ROM, which are generated at both
the intercellular and intracellular level [17]. XO (EC
1.1.3.22) has been postulated as one of the primary
intracellular sources of ROM and its activity level is
reported to increase in several disorders including
brain tumors [18]. It catalyzes the oxidation of hypo-
xanthine to xanthine and of the latter to uric acid.
The enzyme derives from an NAD-dependent dehy-
drogenase by proteolysis [19] or by reversible oxida-
tion of sulfhydryl groups [20]. While oxidizing its
substrate, XO (in its oxygen-dependent form) gener-
ates partially reduced oxygen moieties such as super-
oxide anion radical and hydrogen peroxide as by-
product, which can further be converted to a highly
reactive hydroxyl radical by the Haber^Weiss and
Fenton reaction [21]. Together, these partially re-
duced oxygen moieties are commonly referred to as
ROM. The hyperactivity of XO would, therefore,
lead to increased production of ROM.
ROM are generally detoxi¢ed by a battery of en-
zymatic and other non-enzymatic antioxidant de-
fenses. An imbalance between the production and
detoxi¢cation of ROM results in oxidative stress,
which, through a number of processes including lipid
peroxidation, lead to necrosis [22]. As can be seen
from the results, administration of TAA to rats
could cause an increase in the levels of biochemical
markers of liver necrosis (Table 1) and also the ac-
tivity of hepatic XO (Table 2). An increase in hepatic
malondialdehyde content of the tissue, which is a
marker of the oxidative damage provides evidence
supporting the role of XO-derived ROM in the ne-
crotic process by TAA (Fig. 4).
Reducing the oxidant production in cell by sup-
pressing the radical reactions is one of the major
protective mechanisms of the body under conditions
of oxidative stress. Prophylactic treatment of rats
with AP, an inhibitor of XO [23], is observed in
this study to restore the normal levels of various bio-
chemical parameters altered in the necrotic tissue
(Figs. 1^4). As already discussed, ROM can perturb
the structural integrity of the cell, for example, by
causing the peroxidation of membrane lipids rich in
unsaturated fatty acids, thereby resulting in the re-
lease of cytosolic enzymes from liver cells into the
plasma. Treatment with AP seems to result in the
reduced generation of ROM, thus preventing the
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damage, as is evident by the inhibition of the release
of cytosolic enzymes from the cell. Changes in the
hepatic malondialdehyde content prove in part that
the anti-hepatotoxic e¡ects of the pretreatment with
AP are due to the inhibition of free radical forma-
tion. The e¡ect of AP was so pronounced that it
could cause an appreciable increase in survival rate
in rats given a highly toxic dose of TAA (Fig. 7).
XO inhibitor AP may further help reduce the tis-
sue injury by acting as direct free radical scavenger
[23]. The protective e¡ect of AP on TAA-induced
mortality in rats, however, does not appear to be
due to its antioxidant function. To clarify this point,
tungsten was tested for its protective e¡ect on TAA-
induced lethality in rats. Tungsten is a XO inhibitor
and, unlike AP, is not reported to act as a free rad-
ical scavenger [24]. When administered as ST to ex-
perimental animals, tungsten inhibits the activity of
XO by slowly replacing molybdenum, the cofactor of
the enzyme. As shown in Fig. 8, the survival studies
clearly demonstrate that tungsten pretreatment can
protect the rats against the life-threatening TAA hep-
atotoxicity, indicating that the liver necrosis is con-
tributed to by ROM produced by XO, which is sig-
ni¢cantly induced in TAA treated rats. It, therefore,
can be said that xanthine^XO system plays an im-
portant role in TAA hepatotoxicity.
To mitigate and repair the damage initiated by
ROM, cells have evolved complex antioxidant sys-
tems, which help in detoxi¢cation. Earlier hypotheses
cited to understand the oxidative damage by various
chemical compounds suggest that oxidative stress
will also occur if the detoxi¢cation mechanisms are
impaired. The level of reduced GSH, which consti-
tutes one of the physiologically important protective
mechanisms to curtail progression of tissue damage
[25] is generally a¡ected under conditions of oxida-
tive stress. Profound depletion of GSH may lead to
necrosis, as its unavailability will make the tissue
susceptible to damage by free radicals, which are
produced in excess under stress conditions. During
the present investigation, we observed a decrease in
GSH content of the hepatic tissue in TAA treated
rats (Table 2).
Depletion of GSH in the liver after the injection of
TAA supports the view that radical reactions take
place extensively in the liver during necrosis. Admin-
istration of AP prior to TAA is observed to result in
a dose-dependent increase in the hepatocyte GSH
level (Fig. 5), con¢rming that the damage is oxida-
tive. The tissue GSH content, however, increased
largely in the AP30+TAA group more than that in
the control group. Reduced GSH is a unique cellular
protective agent which acts as both a nucleophilic
scavenger of numerous compounds and their metab-
olites, converting electrophilic centers to thioether
bonds, and as a cofactor in the GSH peroxidase-
mediated destruction of hydroperoxides. Studies
with chemicals like acetaminophen [26] and bromo-
benzene [27] have very clearly demonstrated that bio-
activation of these chemicals followed by GSH ad-
duct formation causes depletion of cytosolic GSH
and oxidative stress. TAA, a substrate for the £a-
vin-dependent monooxygenase present in the micro-
somes [28], is converted to toxic metabolites, which
may be conjugated with GSH to facilitate their elim-
ination. This excess demand of GSH may initiate the
cellular response that causes an increase in the de
novo synthesis of GSH, which is also required to
counteract the cytotoxic e¡ects of XO-derived
ROM. Following the inhibition of XO, the produc-
tion of ROM was also reduced and, therefore, much
of the GSH pool of the tissue remained unused. This
may provide an explanation for the large increase in
hepatic GSH content in the group of rats pretreated
with AP followed by TAA.
Analysis of the results presented in this paper
clearly points out that there is an overall increase
in the activity of liver XO, hepatic malondialdehyde
content and the serum enzymes associated with liver
necrosis. Hepatocyte GSH (reduced form) content
was, as expected, lowered in rats receiving TAA.
The results suggest that oxidative stress plays a cru-
cial role in the necrotic process induced by TAA.
Fig. 8. E¡ect of tungsten pretreatment on TAA-induced lethal-
ity in rats. Dose and other details have been described in Sec-
tion 2. TAA: thioacetamide; ST: sodium tungstate. A higher
survival rate in tungsten pretreated group of rats can be seen.
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Pretreatment with AP followed by TAA is observed
to attenuate the pro-oxidant e¡ect as well as to nor-
malize the toxin-mediated rise in aminotransferases
and alkaline phosphatase activity levels. The protec-
tion against necrosis by AP seems to be the result of
the inhibition of XO-catalyzed generation of ROM.
Suppression of ROM generation by XO inhibitors
has previously been shown to ameliorate the oxida-
tion of biomolecules in other systems [18]. An in-
crease in the survival rates in rats given the enzyme
inhibitor prior to the administration of the lethal
dose of TAA further strengthens the proposal that
an increase in XO activity is a contributing factor in
TAA-induced liver necrosis.
The mechanism by which XO is induced in the
TAA treated group of rats is not clear. A possible
explanation of this may be the oxidation of xanthine
dehydrogenase by TAA itself or by the by-products
generated during TAA metabolism. Xanthine dehy-
drogenase has been reported to undergo reversible
oxidative alteration at its sulfhydryl group to form
XO in vitro [19]. Conversion of xanthine dehydroge-
nase to XO might be a consequence of the intermedi-
ates generated as a result of primary or secondary
oxidative reactions initiated by TAA within the bio-
logical system.
In summary, in these studies the administration of
the hepatotoxic compound TAA is reported to cause
an increase in the activity of rat liver XO, which
through the generation of ROM can damage the
tissue. The hepatic injury can be prevented by the
administration of enzyme inhibitor AP in a dose-de-
pendent manner. Inhibition of the enzyme activity
and the concomitant reduction of oxidative stress,
as manifested by a decrease in hepatic lipid peroxi-
dation in rats pretreated with AP led us to suggest
that the oxidant by-products generated during XO-
catalyzed reaction play a crucial role in liver necrosis
and that suppressing the XO-catalyzed generation of
ROM can protect the tissue against necrosis. Further
studies would be necessary to determine whether
these results may have therapeutic applications in
the future.
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